UNDP's commitment to addressing HIV and other major health and development challenges is based on the principles that health is a driver for and an indicator and outcome of development.
As outlined in the UNDP Strategic Plan 2022-2025, UNDP’s support to countries aims to eradicate poverty in all its forms and dimensions, accelerating structural transformation for sustainable development and supporting governments to build resilience to shocks and crises.
UNDP defines capacity development as the process through which individuals, organizations and societies obtain, strengthen and maintain the capabilities to set and achieve their own development objectives over time.
Strong partnerships are the cornerstone of UNDP's work to strengthen systems for health. In its support to countries UNDP works closely with other United Nations entities, development organizations, civil society organizations, the private sector, academia and key populations to develop resilient and sustainable systems for health.
The effectiveness of UNDP's model of health programme support, with its emphasis on end-to-end capacity development, is evident in the results of its long-standing partnership with the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund).
Whether in its role as an implementing partner managing large-scale HIV, TB, and malaria programmes funded by the Global Fund or as a technical assistance
Investments in resilient and sustainable systems for health lay the foundation for the effective and equitable delivery of HIV, tuberculosis (TB) and malaria.
Human rights barriers include stigma and discrimination, punitive laws, policies and practices, violence, harassment, gender, and social and economic inequalities.
People most affected by HIV, tuberculosis (TB) and malaria are often the same people who are marginalised and have limited or no access to health care.
Gender equality is essential to achieving health and well-being for all, accelerate progress towards the health-related Sustainable Development Goal (SDG) targets and ensuring that no one is left behind.
The quality of health products has to be ensured from manufacturing up to the point of use. Quality assurance (QA) is an overarching element to the whole PSM cycle, beyond the prequalification of health products, to ensure compliance with WHO and national standards. Transportation, storage, distribution and use conditions impact the quality of health products.
“Quality assurance is a wide-ranging concept covering all matters that individually or collectively influence the quality of a product. It is the totality of the arrangements made with the object of ensuring that pharmaceutical products are of the quality required for their intended use.” – World Health Organization
Prequalification
“The activities undertaken in defining a product or service need, seeking expressions of interest from enterprises to supply the product or service, and examining the product or service offered against the specification and the facility where the product or service is prepared against common standards of good manufacturing practice (GMP). Prequalification is required for all pharmaceutical products regardless of their composition and place of manufacture/registration.” – World Health Organization
Quality control
“Quality control covers all measures taken, including the setting of specifications, sampling, testing and analytical clearance, to ensure that starting materials, intermediates, packaging materials and finished pharmaceutical products conform with established specifications for identity, strength, purity and other characteristics.” – World Health Organization
Pharmaceutical waste management
Pharmaceutical waste management is regarded to be an integral part of quality assurance within supply chain management and the product lifecycle, as a result of the use and/or expiry of health products. Inadequate and inappropriate handling of healthcare waste can have serious public and global health consequences and a significant impact on the environment. Refer to the Health care waste management page for further information.
UNDP’s approach
Upon governments’ requests, UNDP can provide support for identifying and assessing health products in accordance with World Health Organization (WHO) and international standards. It can also mobilize a pool of international experts to assist the regulatory authorities in the identification, assessment and prequalification of health products, in accordance with WHO and international standards. The same experts can be mobilized to provide training sessions in quality assurance to counterparts (regulatory authorities or central medical stores) in countries based on specific requests submitted by the authorities.
UNDP also provides support to the development of infrastructure and capacities in national quality control laboratories in several countries, in close collaboration with the WHO prequalification programme for quality control laboratories. In order to ensure that the quality of health products is maintained in the supply chain, UNDP also promotes the use of appropriate vehicles and containers for the transport of health products and the use of data loggers for controlling the storage and distribution of medicines. This implies the training of staff on the use, collection and analysis of data.
UNDP has also developed a quality assurance planning tool, to help to carry out assessments at the country level throughout the supply chain cycle. This includes looking at all the aspects in the procurement and supply chain management (PSM) cycle that relate to ensuring the quality of the medicines and health products, from selection to use and waste management. The application of this tool is designed to be carried out in coordination with the national regulatory authority, WHO and other partners involved in health PSM in the country. The end result is the identification of gaps and the definition of activities to address and prioritize the identified needs, coordination of financial resources, and elaboration of an operational plan to strengthen the quality assurance in the national supply chain.
UNDP support to quality assurance: country examples
Zimbabwe obtained prequalification status from the World Health Organization (WHO) for its chemical laboratory to perform quality control (QC) in 2014 and it is in the process of getting its microbiology laboratory WHO-prequalified. UNDP is also supporting Sudan and Afghanistan to upgrade their QC laboratories to meet the WHO prequalification status.
In Kyrgyzstan and Uzbekistan, UNDP supported the national regulatory authority laboratories in assessment of their readiness to be included on the list of QC laboratories meeting requirements from the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) (ISO/IEC 17025) as well as in submission of questionnaires on the technical proficiency of QC drug testing laboratories for the Global Fund attestation. Both laboratories have been included in the list of ISO 17025 QC laboratories compliant with the Global Fund quality assurance requirements.
In Zimbabwe, UNDP is also providing support to the national regulatory authority to address the priorities identified in the institutional development plan developed jointly with WHO. UNDP plans to provide further support on the development of quality assurance systems in national procurement agencies.
WHO Prequalification Programme for Medicines, WHO Prequalification Programme for In-Vitro Diagnostics, WHO Prequalification of Vaccines, WHO Prequalification of Vector Control Products, WHO/UNFPA Prequalification Programme for Male Latex Condoms, WHO/UNFPA Prequalification...
World Health OrganizationA quality control laboratory prequalification has been established by WHO to enhance in-country capacities for the quality control of medicines.
WHO has also established general requirements for quality assurance systems for procurement agencies to ensure that transactions with partners ultimately result in procuring health products of the best possible quality:
Relevant sections include:Annex 9: Guidelines on the implementation of the WHO certification scheme on the quality of pharmaceutical products moving in international commerceAnnex 10: Good reliance practices in the regulation...
Countries can benefit from WHO guidance and tools for strengthening national regulatory authority functions, as well as for enabling and speeding up registration of WHO-prequalified and stringent national regulatory authority-registered...